Profund Advisors LLC Purchases 5,822 Shares of Abbott Laboratories $ABT

Profund Advisors LLC increased its position in shares of Abbott Laboratories (NYSE:ABT) by 25.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,291 shares of the healthcare product maker’s stock after buying an additional 5,822 shares during the period. Profund Advisors LLC’s holdings in Abbott Laboratories were worth $3,545,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ABT. Harbor Capital Advisors Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $27,000. Cloud Capital Management LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter valued at $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories during the 3rd quarter valued at $31,000. Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter valued at $33,000. Finally, Copia Wealth Management acquired a new position in shares of Abbott Laboratories during the 3rd quarter valued at $38,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of a number of research reports. Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Bank of America dropped their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Citigroup dropped their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Wells Fargo & Company dropped their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Finally, Oppenheimer dropped their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Stock Performance

ABT opened at $88.81 on Wednesday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company’s fifty day moving average price is $98.14 and its two-hundred day moving average price is $112.73. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a market cap of $154.70 billion, a price-to-earnings ratio of 24.88, a PEG ratio of 1.47 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the company posted $1.09 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were issued a dividend of $0.63 per share. The ex-dividend date was Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Activity

In other news, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.